Teva And Ranbaxy Launch Generic Zocor With 180-Day Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite an eleventh-hour suit by Sandoz, FDA approved the generic companies’ ANDAs for simvastatin.
You may also be interested in...
Generic Drug Sales Grew 22 Percent In 2006 Driven By Unbranded Zocor, Plavix
Sales of Teva's simvastatin were $911 million, and sales of Apotex's clopidogrel were $902 million, according to IMS Health data.
Generic Drug Sales Grew 22 Percent In 2006 Driven By Unbranded Zocor, Plavix
Sales of Teva's simvastatin were $911 million, and sales of Apotex's clopidogrel were $902 million, according to IMS Health data.
Generic Exclusivity On Delisted Patents Upheld By Appeals Court
In ruling on the Zocor case, court finds FDA requirement that a generic company must be involved in patent litigation to retain exclusivity is unlawful.